Takeda Pharmaceutical Co. Ltd. has received a Complete Response Letter (CRL) from the US Food and Drug Administration for its 2020 new drug application for Eohilia (TAK-721), an oral suspension of the corticosteroid budesonide for eosinophilic esophagitis (EoE).
The decision marks another setback for one of the most advanced products in the major Japanese firm’s “Wave 1” pipeline of near-term assets, a portfolio of 12 new molecular entities...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?